S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.30 (-1.57%)
AAPL   120.07 (-1.63%)
MSFT   227.07 (-0.22%)
FB   258.10 (+1.05%)
GOOGL   2,035.00 (+1.17%)
TSLA   621.99 (-4.78%)
AMZN   2,978.97 (-0.87%)
NVDA   495.08 (-3.34%)
BABA   230.25 (-2.55%)
CGC   31.01 (-6.71%)
GE   13.62 (+1.34%)
MU   84.35 (-5.34%)
NIO   39.30 (-5.37%)
AMD   77.79 (-3.80%)
T   28.93 (+0.73%)
F   11.93 (-1.97%)
ACB   9.81 (-6.21%)
DIS   188.05 (-2.19%)
BA   225.40 (-1.38%)
NFLX   511.28 (-1.81%)
BAC   36.52 (+0.27%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.30 (-1.57%)
AAPL   120.07 (-1.63%)
MSFT   227.07 (-0.22%)
FB   258.10 (+1.05%)
GOOGL   2,035.00 (+1.17%)
TSLA   621.99 (-4.78%)
AMZN   2,978.97 (-0.87%)
NVDA   495.08 (-3.34%)
BABA   230.25 (-2.55%)
CGC   31.01 (-6.71%)
GE   13.62 (+1.34%)
MU   84.35 (-5.34%)
NIO   39.30 (-5.37%)
AMD   77.79 (-3.80%)
T   28.93 (+0.73%)
F   11.93 (-1.97%)
ACB   9.81 (-6.21%)
DIS   188.05 (-2.19%)
BA   225.40 (-1.38%)
NFLX   511.28 (-1.81%)
BAC   36.52 (+0.27%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.30 (-1.57%)
AAPL   120.07 (-1.63%)
MSFT   227.07 (-0.22%)
FB   258.10 (+1.05%)
GOOGL   2,035.00 (+1.17%)
TSLA   621.99 (-4.78%)
AMZN   2,978.97 (-0.87%)
NVDA   495.08 (-3.34%)
BABA   230.25 (-2.55%)
CGC   31.01 (-6.71%)
GE   13.62 (+1.34%)
MU   84.35 (-5.34%)
NIO   39.30 (-5.37%)
AMD   77.79 (-3.80%)
T   28.93 (+0.73%)
F   11.93 (-1.97%)
ACB   9.81 (-6.21%)
DIS   188.05 (-2.19%)
BA   225.40 (-1.38%)
NFLX   511.28 (-1.81%)
BAC   36.52 (+0.27%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.30 (-1.57%)
AAPL   120.07 (-1.63%)
MSFT   227.07 (-0.22%)
FB   258.10 (+1.05%)
GOOGL   2,035.00 (+1.17%)
TSLA   621.99 (-4.78%)
AMZN   2,978.97 (-0.87%)
NVDA   495.08 (-3.34%)
BABA   230.25 (-2.55%)
CGC   31.01 (-6.71%)
GE   13.62 (+1.34%)
MU   84.35 (-5.34%)
NIO   39.30 (-5.37%)
AMD   77.79 (-3.80%)
T   28.93 (+0.73%)
F   11.93 (-1.97%)
ACB   9.81 (-6.21%)
DIS   188.05 (-2.19%)
BA   225.40 (-1.38%)
NFLX   511.28 (-1.81%)
BAC   36.52 (+0.27%)
Log in
NASDAQ:INFI

Infinity Pharmaceuticals Stock Forecast, Price & News

$2.71
-0.19 (-6.55 %)
(As of 03/4/2021 04:00 PM ET)
Add
Compare
Today's Range
$2.48
Now: $2.71
$3.05
50-Day Range
$2.67
MA: $3.65
$5.36
52-Week Range
$0.60
Now: $2.71
$5.98
Volume276,054 shs
Average Volume4.86 million shs
Market Capitalization$174.00 million
P/E RatioN/A
Dividend YieldN/A
Beta2.4
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Infinity Pharmaceuticals logo

Headlines

Infinity Announces Proposed Public Offering of Common Stock
February 11, 2021 |  finance.yahoo.com
Why Infinity Pharmaceuticals Is Skyrocketing Today
February 11, 2021 |  finance.yahoo.com
F. Hoffmann-La Roche Ltd: Roche reports solid results in 2020
February 4, 2021 |  finanznachrichten.de
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INFI
CUSIP45665G30
Phone617-453-1000
Employees25
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.05 million
Book Value$0.14 per share

Profitability

Net Income$-47,060,000.00
Net Margins-2,592.65%

Miscellaneous

Market Cap$174.00 million
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.35 out of 5 stars

Medical Sector

681st out of 1,969 stocks

Pharmaceutical Preparations Industry

329th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$2.71
-0.19 (-6.55 %)
(As of 03/4/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INFI News and Ratings via Email

Sign-up to receive the latest news and ratings for INFI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions

Is Infinity Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Infinity Pharmaceuticals stock.
View analyst ratings for Infinity Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Infinity Pharmaceuticals?

Wall Street analysts have given Infinity Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Infinity Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a decline in short interest in February. As of February 12th, there was short interest totaling 575,400 shares, a decline of 18.4% from the January 28th total of 705,500 shares. Based on an average trading volume of 3,460,000 shares, the short-interest ratio is currently 0.2 days.
View Infinity Pharmaceuticals' Short Interest
.

When is Infinity Pharmaceuticals' next earnings date?

Infinity Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Infinity Pharmaceuticals
.

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) released its earnings results on Monday, November, 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The biotechnology company had revenue of $0.50 million for the quarter, compared to analysts' expectations of $0.22 million. Infinity Pharmaceuticals had a negative net margin of 2,592.65% and a negative trailing twelve-month return on equity of 1,358.77%.
View Infinity Pharmaceuticals' earnings history
.

How has Infinity Pharmaceuticals' stock been impacted by COVID-19?

Infinity Pharmaceuticals' stock was trading at $1.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, INFI stock has increased by 168.3% and is now trading at $2.71.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for INFI?

5 brokers have issued 12-month target prices for Infinity Pharmaceuticals' shares. Their forecasts range from $1.00 to $9.00. On average, they expect Infinity Pharmaceuticals' stock price to reach $6.25 in the next twelve months. This suggests a possible upside of 130.6% from the stock's current price.
View analysts' price targets for Infinity Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the following people:
  • Ms. Adelene Q. Perkins, Chairman & CEO (Age 61, Pay $1.13M)
  • Dr. Lawrence E. Bloch, Pres & Treasurer (Age 55, Pay $701.62k)
  • Dr. Jeffery L. Kutok, Chairman of Scientific Advisory Board (Age 54, Pay $606.87k)
  • Ms. Melissa Hackel, VP of Fin.
  • Mr. Seth A. Tasker, Chief Bus. Officer (Age 42)
  • Ms. Rossitza Alargova Ph.D., Head of Pharmaceutical Devel.
  • Dr. Brian Schwartz, Consulting Chief Physician (Age 59)
  • Jayne Kauffman, Sr. Exec. Coordinator

What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO?

10 employees have rated Infinity Pharmaceuticals CEO Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among Infinity Pharmaceuticals' employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Infinity Pharmaceuticals' key competitors?

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

Who are Infinity Pharmaceuticals' major shareholders?

Infinity Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.45%), BlackRock Inc. (1.52%), Baker BROS. Advisors LP (0.81%), Northern Trust Corp (0.25%), Callan Capital LLC (0.11%) and JPMorgan Chase & Co. (0.06%).
View institutional ownership trends for Infinity Pharmaceuticals
.

Which major investors are selling Infinity Pharmaceuticals stock?

INFI stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, and Northern Trust Corp.
View insider buying and selling activity for Infinity Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Infinity Pharmaceuticals stock?

INFI stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Callan Capital LLC, JPMorgan Chase & Co., Private Wealth Advisors Inc., and BlackRock Inc..
View insider buying and selling activity for Infinity Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $2.71.

How much money does Infinity Pharmaceuticals make?

Infinity Pharmaceuticals has a market capitalization of $174.00 million and generates $3.05 million in revenue each year. The biotechnology company earns $-47,060,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

How many employees does Infinity Pharmaceuticals have?

Infinity Pharmaceuticals employs 25 workers across the globe.

What is Infinity Pharmaceuticals' official website?

The official website for Infinity Pharmaceuticals is www.infi.com.

Where are Infinity Pharmaceuticals' headquarters?

Infinity Pharmaceuticals is headquartered at 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]


This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.